Abstract

BackgroundIt is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is the most appropriate method for this purpose.MethodsWe identified all double-blind, placebo-controlled, studies that compared at least two fixed doses of second-generation antipsychotic drugs or haloperidol in people with acute schizophrenia or with predominant negative symptoms. For this purpose, we searched multiple electronic databases, the website of the FDA, and the clinical trial database clinicaltrials.gov. The method applied was dose response meta-analyses with a spline model. The outcome was the reduction of the PANSS or BPRS total score from baseline or – for negative symptoms - a negative symptom scale. With this method we identified 95% effective doses (these have also been called “near-to-maximum” doses). We applied linear splines to examine whether the dose-response curves had already reached a plateau. Moreover, the identified dose-response relationships of each drug were used to derive risperidone equivalent doses.ResultsWe identified 67 randomized-controlled trials that were eligible. The following 1mg risperidone equivalent doses were identified: amisulpride 86.6mg/day, aripiprazole 1.9mg/day, asenapine 2.4mg, brexpiprazole 0.56mg clozapine 91mg, haloperidol 1.01mg, iloperidone 3.2mg, lurasidone 23.5mg, olanzapine 2.4mg, paliperidone 13.4/2.1, quetiapine 77mg, risperidone 1mg, sertindole 3.6mg, ziprasidone 30mg.DiscussionFrom a conceptual point of view, dose-response meta-analysis is the most appropriate method to identify maximally effective doses and equivalent doses. The results of this meta-analysis will be compared with other published methods to define dose-response, in particular the minimum-effective dose method, the classical mean dose method, the daily-defined-doses (DDD) method and expert consensus methods. The results of this analysis are likely to provide information with impact for treatment decisions.

Highlights

  • It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs

  • We identified all double-blind, placebo-controlled, studies that compared at least two fixed doses of second-generation antipsychotic drugs or haloperidol in people with acute schizophrenia or with predominant negative symptoms

  • The outcome was the reduction of the Positive and Negative Syndrome Scale (PANSS) or BPRS total score from baseline or – for negative symptoms - a negative symptom scale

Read more

Summary

Background

Long-term maintenance treatment is recommended to control the symptoms of schizophrenia; safety monitoring for longer than the period required to treat an acute exacerbation is warranted. The aim of the present study (Lighthouse extension; NCT01810783) was to assess the long-term safety and tolerability of open-label treatment with brexpiprazole (flexible dose 1–4 mg/day) in adult patients with schizophrenia. Methods: Patients rolled over into this 52-week open-label study from a randomized, double-blind, placebo-controlled, active referenced, Phase 3 study (Lighthouse; NCT01810380). The primary endpoint was safety and tolerability. The mean and mean modal doses of brexpiprazole were 3.07mg/day and 3.18mg/day, respectively; at last visit, 50% of the patients received 4mg/ day. Among patients who took ≥1 dose of brexpiprazole, the incidence of discontinuation due to treatment-emergent adverse events (TEAEs) was 17.2%. TEAEs with an incidence of ≥5.0% were schizophrenia

Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call